INTRODUCTION
PTPN22 encodes the protein tyrosine phosphatase (PTP) LYP, which is a critical gatekeeper of T-cell receptor (TCR) signaling. In T-cells, LYP (lymphoid tyrosine phosphatase) potently inhibits signaling through dephosphorylation of several substrates, including the Src-family kinases Lck and Fyn, as well as ZAP-70 and TCRzeta (1, 2) . Recently, PTPN22 has emerged as an important genetic risk factor for human autoimmunity. Specifically, an R620W missense single nucleotide polymorphism (SNP) (rs2476601) in exon 14 of PTPN22 is associated with type 1 diabetes (T1D) (3), rheumatoid arthritis (4), systemic lupus erythematosus (SLE) (5) , and other autoimmune diseases (reviewed in 6). The R620W substitution occurs within a protein-protein interaction domain and results in a gain of function that inhibits TCR signaling (7, 8) . Reduced TCR signaling has recently been recognized as a risk factor for autoimmunity and affects disease predisposition by multiple mechanisms, including altered thymic selection, reduced T-helper activity, and decreased number/function of regulatory T-cells (9) .
In this study, we sought to determine whether another amino acid substitution, R263Q (G788A, rs33996649) within the catalytic domain of the enzyme, is functional with respect to TCR signaling and phosphatase activity. † The authors wish it to be known that, in their opinion, the first three authors should be regarded as joint First Authors. 
RESULTS
We first compared the effect of the R263Q variant on TCR-induced phosphorylation of intracellular proteins at the single cell level by phospho-specific flow cytometry (Fig. 1A-C) . Compared with the wild-type R263 allele (continuous graphs), the Q263 allele (dotted graphs) was less efficient in reducing the phosphorylation of SLP-76, an early mediator of TCR signaling downstream of LYP (Fig. 1C) . The Q263 variant was also less efficient in inhibiting the TCR-induced activation of extracellular-signal regulated kinase (ERK) (Fig. 1D ) and the TCR-induced activation of an NFAT/AP1 luciferase reporter (Fig. 1E) . Taken together, these data suggest that Q263 is a loss-of-function variant of LYP.
Because the R263Q polymorphism is located within the catalytic domain of the phosphatase, we hypothesized that the apparent loss of function is due to reduced phosphatase activity. Consistent with this notion, the phosphatase activity of the Q263 variant was lower than that of R263 ( Fig. 2A) . To assess this, we generated constructs encoding the catalytic domain of LYP, purified the two allelic variants (Cat-R263 and Cat-Q263, see Fig. 2B ), and assayed their activity on a 14-amino acid peptide derived from the Y394 phosphorylation site of Lck, a physiological substrate of LYP. The Cat-Q263 variant showed lower specific activity than Cat-R263 on the physiological peptide (Fig. 2C) . Cat-Q263 also showed lower activity than Cat-R263 when two non-specific PTP substrates were used ( Fig. 2D and E) . Based on these data, we conclude that the R263Q substitution decreases LYP phosphatase activity.
To determine the structural basis underlying this loss-offunction phenotype, we solved the crystal structures of the catalytic domain of the Q263 LYP mutant and the wild-type allele. Based on our new derivation ( Fig. 3A ; Table 1 ) as well as that recently reported by Yu et al. (10) , the overall structure of Cat-Q263 is similar to that of the wild-type allele. However, the a2 0 helix of Cat-Q263 is significantly displaced (Fig. 3A) as a result of a loss of the stabilizing contact that normally occurs between R263 of a5 and Q34 of a2 0 (Fig. 3B) . Thus, substitution of Q at position 263 disrupts the conformation of the loop between the a1 and a2 0 helices, which has been shown to be LYP-specific and to participate in substrate binding (10) . This results in an extended a2 0 helix that exposes the critical S35 residue toward the outer surface of the enzyme. In addition, the flexible Trp-P20-Glu (WPD) loop that provides the hydrophobic pocket, which buries the phosphotyrosine and stabilizes the phosphoryl-cysteine intermediate, is in an open conformation with Cat-Q263, whereas it is half-closed in wild-type LYP (Fig. 3C) . Furthermore, a comparison of surface electrostatics between Cat-R263 and Cat-Q263 ( Fig. 3D and E) demonstrates that, despite preserving the electropositive nature of the substrate-binding cleft with a hydrophobic boundary, the conformation and depth of the cleft in the Cat-Q263 mutant is different from that of Cat-R263, which could potentially disrupt catalysis. These data provide a plausible molecular mechanism through which the Q263 variant leads to a loss of function. Recently, Yu et al. (10) identified a specific small molecule inhibitor of LYP called IC-11. Co-crystallization analysis showed that IC-11 extensively interacts with the same a1-a2 0 loop, which is affected by the R263Q polymorphism (10) . Therefore, we also assessed the inhibitory action of IC-11 on Cat-R263 and Cat-Q263, and found that IC-11 is significantly less potent on the Q263 variant of the phosphatase (Fig. 4) , which lends further support to our model of the structural effect of the R263Q polymorphism.
Given that the R620W variant with a gain-of-function effect predisposes individuals to autoimmunity, we reasoned that the loss-of-function nature of the R263Q polymorphism may have a protective effect against autoimmunity. We therefore examined the impact of the R263Q variant on patients with SLE, a systemic autoimmune disease. We genotyped a cohort of 881 SLE patients and 1133 healthy Controls of Caucasian ancestry (Spain) and observed a significant protective effect of the Q263 allele which was present at a higher frequency in Controls compared with Cases [odds ratios (OR) 0.58, 95% confidence interval (CI) 0.38-0.86, P ¼ 0.006] ( Table 2 ). To confirm this association, we genotyped the R263Q genetic variant in three independent replication populations (Italian, Argentinean and Caucasian North American). Genotype frequencies were in Hardy -Weinberg equilibrium in patients and Controls in all four populations. The Q263 protective effect was observed in all three cohorts, although the P-values did not reach significance likely due to their smaller sample sizes. The Breslow -Day test showed homogeneity of the four populations allowing us to perform a combined analysis with a total of 2093 SLE patients and 2348 Controls, which confirmed the protective effect of the Q263 loss-of-function allele (pooled OR 0.63, 95% CI 0.47-0.84, P ¼ 0.0017) ( Table 2 ). It should be noted that these results are obtained from Caucasians and we cannot exclude the possibility that underlying genetic substructure within European-derived populations may affect the association of the R263Q with SLE. This may be particularly relevant in the US cohort, which is a combination of Cases and Controls from two recruitment sites. Previous studies demonstrated that the R620W and the R263Q non-synonymous polymorphisms are in independent PTPN22 haplotypes (11, 12) . Therefore, it could be suggested that these genetic variants exert independent effects on genetic susceptibility to SLE. To test this hypothesis, we first examined linkage disequilibrium (LD) between the R620W and R263Q polymorphisms and observed that these variants were completely independent (r 2 ¼ 0). Although the low frequency of the R263Q variant precluded a complete test of interaction between the two SNPs, we performed an analysis with the R263Q SNP by conditioning on R620W and observed that the association of the R263Q polymorphism with SLE is independent of the R620W SNP (P ¼ 0.003 for the association of R263Q polymorphism conditioned on R620W).
Because the R620W SNP, which predisposes to a variety of autoimmune-related disorders, shows extreme frequency variations among ethnic groups, we sought to determine whether the R263Q SNP also shows population-specific frequency variations. In addition to the four SLE cohorts described earlier, we also genotyped the SNP in African-American, Caucasian, Asian, and Hispanic Control individuals and observed that the frequency of Q263 carriers is 4% in Caucasians and Hispanics, while carriers are even rarer among African-Americans and Asians (Table 3) . Thus, the R263Q SNP does not appear to have significant allele
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Human Molecular Genetics, 2009, Vol. 18, No. 3 frequency differences across ethnicities but it remains to be determined whether larger variation occurs across different European populations, analogous to what has been reported for the R620W SNP (13) . Lastly, when we compared the sequences of the catalytic domains from all available LYP homologs in the NCBI (National Center for Biotechnology Information) database we observed that, with the exception of humans, who contain an R at position 263, the amino acid at the homologous site in all of the other species is invariably a Q (Fig. 5) , demonstrating that the ancestral enzyme encodes Q at position 263. Because it has been hypothesized that the PTPN22 locus is under positive selective pressure 14), it would be interesting to determine whether the R263 allele also rose to such a high frequency in humans as a result of positive selection, since it can be considered a 'gain-of-function' allele relative to the ancestral Q263 variant.
DISCUSSION
Reduced TCR signaling has recently emerged as an important causal factor in the development of autoimmunity. In this regard, the R620W SNP in PTPN22, which reduces TCR signaling as a result of increased phosphatase activity, predisposes to several autoimmune disorders. In contrast, we demonstrate that a loss-of-function variant (R263Q), which is less effective in reducing TCR signaling, protects against SLE. The bi-directional association of PTPN22 with autoimmunity has potentially important therapeutic implications since it has been proposed that inhibition of LYP activity, which would presumably enhance TCR signaling, could help prevent or treat such diseases (10) . Stimulation of the TCR through a different mechanism has been shown to have curative effects in mouse models of T1D and to benefit human autoimmunity patients (15) . In addition, the allele-specific inhibitory effect of IC-11 on LYP activity has implications for individualized therapeutic strategies (16) . Our data suggest that patients carrying the Q263 variant might not benefit as much as non-carriers from inhibitors of LYP. Moreover, these experiments provide independent confirmation of our structural derivation as well as the interaction model proposed by Yu et al. for IC-11.
Considering that the PTPN22 R620W polymorphism predisposes to several autoimmune diseases, it is likely that the PTPN22 Q263 allele associates with multiple autoimmune diseases as well. For example, recently Skinningsrud et al. (17) reported a protective trend for the Q263 allele in Addison's disease. However, compared with the predisposition conferred by the R620W variant, the protective effect of R263Q appears to be weaker and, interestingly, it does not extend to T1D (12) . One explanation for this observation is that a loss-of-function effect on TCR signaling is more easily compensated for than a gain-of-function effect. In addition, the quantitative thresholds between TCR signaling and the development of disease pathology are likely different in various autoimmune diseases. We speculate that for example a larger reduction in signal transduction through the TCR may be required for predisposition to SLE than to T1D. Experimental evidence is required to determine whether this model is indeed biologically plausible.
MATERIALS AND METHODS

Human subjects and genotyping
The Spanish, Argentinean and Italian SLE Cases and their clinical characteristics have all been previously described (18, 19) . The 457 European-derived SLE patients recruited in CA, USA, were an extension of the previously reported 60 multiplex and 258 simplex SLE families (20) and 358 normal Controls of European descent were also ascertained at the same site. In addition, 122 SLE patients and 209 Controls of European ancestry were recruited in Houston, TX, USA, as described (21) . For the US cohort, self-reported ethnic origin of the four grandparents of the SLE patient and Controls (if known) were used to classify European ancestry. All cases fulfill the 1982 American College of Rheumatology criteria for the classification of SLE (22) . All participating subjects provided informed consent for the study. The study was approved by the various Institutional Review Boards and Ethnical Committees at each of the participating locations. The genotyping for SNP rs33996649 was performed using a Custom-Taqman-SNP-Genotyping-Assay (Applied Biosystems, Foster City, CA, USA). The primer sequences were: forward 5 0 TTTGAACTAATGAAGGCCTCTGTGT 3 0 and reverse 5 0 ATTCCTGAGAACTTCAGTGTTTTCAGT 3 0 . The specific minor groove binder probe sequences were 5 0 TTGATCCGGGAAATG 3 0 and 5 0 TTGATCCAGGAAATG 3 0 .
Plasmids, antibodies and reagents
Full-length LYP was cloned in the BamHI site of the plasmid pEF5 (23) , which allows the expression of constructs in fusion with an N-terminal HA tag, and under control of the EF1alpha (elongation factor 1 alpha) promoter. Mutagenesis was performed by site-directed mutation primers, using Pfu-Ultra polymerase (Stratagene, San Diego, CA, USA) for PCR (polymerase chain reaction) amplification; all mutants were assessed by full-length sequencing. The anti-LYP antibody Note:
, where I i (j) is the i-th measurement of reflection j and ,I(j). is the overall weighted mean of i measurements. R cryst ¼ ShklkFoj-jFck/ShkljFoj, 7% of the reflections were excluded for the R free calculation. 
Cell culture, transfections, cell stimulation
Jurkat T leukemia cells expressing SV-40 large T Antigen (JTAg) (24) were kept at logarithmic growth in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% fetal calf serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 10 mM HEPES pH 7.3, 2.5 mg/ml D-glucose, 100 units/ml of penicillin and 100 mg/ml streptomycin. Transfections were performed by electroporation as described (7). Short-term stimulation of JTAg cells was achieved by using C305 hybridoma (25) supernatants.
Phospho-flow cytometry
The anti-LYP antibody was conjugated with AF488 using a commercial conjugation kit (Pierce, Rockford, IL, USA) and the AF488-conjugated antibody was optimized for detection of LYP expression in flow cytometry (data not shown). Phospho-flow cytometry was performed on transfected JTAg cells following the manufacturer's instructions (BD Biosciences Pharmingen). Cells were fixed with BD Cytofix buffer, permeabilized using BD Phosflow buffer III and stained with AF488-conjugated anti-LYP and PE-conjugated anti-pSLP-76 (Tyr128) antibodies. Cell fluorescence was assessed on a Cytomics FC500 cytometer (Beckman Coulter, Fullerton, CA, USA) at the USC Immune Monitoring Core. Flow cytometry data analysis and graph preparation were carried out using FlowJo (Tree Star, Inc., Ashland, OR, USA). Differences between distributions were calculated by Overton subtraction (26) . The sampling error in C305-stimulated JTAg cells was evaluated by measuring the average + SD Overton subtraction% of three independent replicates and was 2.5 + 0.6% for the anti-pSLP-76 antibody.
Immunoprecipitations and western blot analysis
For immunoprecipitations (IPs), cells were lysed in 20 mM Tris-HCl pH 7.4, 150 mM NaCl, and 1 mM EDTA (TNE buffer), with 1 mM phenylmethanesulphonylfluoride, 10 mg/ml Table 2 . 576
aprotinin/leupeptin, 10 mg/ml soybean trypsin inhibitor, and 10 mM sodium orthovanadate. Anti-HA antibody was added to the lysates, followed by sepharose-conjugated Protein G Sepharose (GE healthcare, Piscataway, NJ, USA) to precipitate the antibody -antigen complex. The beads were washed four to five times in lysis buffer, and resuspended in SDS sample buffer. Proteins were run on denaturing SDS-polyacrylamide gels (Invitrogen, Carlsbad, CA, USA), and transferred to nitrocellulose filters (Hybond ECL, GE Healthcare). Western blots were performed using appropriate dilutions of unconjugated primary antibodies, followed by HRP(horseradish peroxidase)-conjugated secondary antibodies (purchased from GE Healthcare). Filters were then subjected to a chemiluminescent detection protocol using ECL Plus (GE Healthcare) followed by autoradiography (using films from Kodak, Rochester, NY, USA).
Luciferase assays
Luciferase assays were performed as previously described (7). The NFAT/AP1 reporter plasmid (kindly provided by Dr Gerald Crabtree, Stanford University, Stanford, CA, USA) carries three tandem copies of the distal NFAT/AP1 composite element of the human IL2 promoter (24) which are cloned upstream of the minimal IL2 promoter (from 289 to þ51) and the luciferase reporter gene. The NFAT/AP1 reporter plasmid and the Control pGL3 plasmid, driving constitutive expression of Renilla luciferase, were co-transfected in JTAg cells with variable amounts of the appropriate HA -LYP constructs. Cells were subjected to TCR stimulation with anti-CD3 [OKT3, purified from hybridoma supernatants (27) ] for 7 h. Luciferase assays were then performed in triplicate on cell lysates using the dual luciferase kit from Promega according to the manufacturer's instructions, and luminescence measured on a Perkin Elmer 1420 Multilabel Counter Victor III V plate reader (Perkin-Elmer, Turku, Finland). The difference in the ratio between firefly and Renilla luciferase activity in stimulated versus unstimulated cells (TCR-induced increased activation of reporter) was then plotted against the expression of LYP assessed by densitometric scanning of anti-HA blots of total lysates.
Purification of recombinant proteins
The catalytic domain (amino acid 2 -309) of LYP -R263 or LYP -Q263 (Cat-R263 and Cat-Q263) were cloned between the BamHI and the XhoI sites of the pET28a vector (EMD Chemicals, Gibbstown, NJ, USA) and expressed in BL21 Escherichia coli cells in fusion with a thrombin-cleavable N-terminal 6xHis tag. Recombinant Cat was isolated from lysates of IPTG(isopropyl b-D-1-thiogalactopyranoside)-induced bacteria by two steps of affinity chromatography. Bacterial lysates were loaded on a Ni 2þ -NTA column (Qiagen, Inc., Valencia, CA, USA) and the untagged protein was eluted by incubating the column with thrombin, followed by removal of thrombin through a second step on a benzamidin-sepharose column. As shown in Fig. 2B , the purified proteins were evident as single 37 kDa bands on denaturing SDS -polyacrylamide gels and their purity was at least 99% by Coomassie staining. Protein concentration was quantified by assessing absorbance of protein solutions at 280 nm, and confirmed by comparison with BSA standards on Coomassie-stained SDS -denaturing gels.
Phosphatase assays
In order to detect the phosphatase activity of full-length LYP immunoprecipitated from transfected JTAg cells, immunoprecipitates were washed three times in 100 mM Bis -Tris pH 6.0, and resuspended in phosphatase buffer (50-100 mM Bis -Tris, pH 6.0, 1 -5 mM DTT). IPs were incubated with 0.5 mM 6,8-di-fluoro-4-methylumbelliferyl phosphate (DiFMUP), and dephosphorylation of DiFMUP was monitored continuously by measuring the increase in fluorescence (l exc ¼ 355 nm and l em ¼ 460 nm) at 60 s intervals for 30 min. The LYPattributable activity of IPs measured in triplicate was calculated by subtracting the aspecific activity (also measured in triplicate) of identical IPs performed from lysates of cells transfected with inactive LYP -S227. The LYP-attributable activity was subsequently normalized for LYP expression as assessed by anti-HA blots of fractions of IPs taken before resuspension in the final phosphatase buffer. The activity of Cat was detected in the phosphatase buffer using paranitrophenylphosphate (p-NPP), or DiFMUP, or a 14 amino acid pTyr peptide ARLIEDNE(pY)TAREG, derived from the Lck-Tyr394 phosphorylation site (14LckpY394). Dephosphorylation of DiFMUP was detected as described earlier.
When the pTyr-peptide was used as substrate, the reaction was stopped by addition of BIOMOL GREEN TM (Biomol International, LP, Plymouth Meeting, PA, USA) and the phosphate released was detected by measuring the absorbance at 595 nm. When p-NPP was used as substrate, the reaction was stopped by addition of 1.0 M NaOH, and the activity was detected by monitoring the absorbance of paranitrophenol at 405 nm. Fluorescence and absorbance were measured using the previously mentioned plate reader. The phosphatase activity measured in triplicate was corrected for the aspecific signal of identical reactions performed also in triplicate without addition of enzyme. Data were fit to the Michaelis -Menten equation or to the Michaelis -Menten with substrate inhibition equation (28) , and kinetic parameters were calculated for each substrate. Amount of enzymes and time of incubation in all phosphatase assays were optimized in order to ensure initial rate conditions.
Protein crystallization and structure solution
Crystallization and data collection. Crystals of the Cat-Q263 variant were obtained using the vapor diffusion method at 188C using a precipitant containing 2.0 M ammonium sulfate, 1% ethanol, 0.2 M sodium-potassium phosphate in 0.1 M MES, pH 6.2 in the buffer and pH 5.8 in the drop. Crystals appeared within 3 -5 days and grew to full size in 1.5 weeks. Plate-shaped crystals were flash frozen after a quick soaking in a cryo solution containing 15% glycerol, 2.0 M ammonium sulfate, 0.2 M sodium -potassium phosphate in 0.1 M MES (pH 6.2) and diffraction data up to 2.65 Å were collected at in-house R-AXIS IVþþ image plate. The data were processed using HKL2000, and data statistics are shown in Table 1 .
Human Molecular
Structure determination and refinement. The structure of the Cat-Q263 variant was solved by molecular replacement method (MOLREP) using the coordinates of wild-type Cat as the search model. The residue at mutation site and some of its neighbors were mutated to Ala in the search model. The N-terminal a1 0 and a2 0 helices and several other loops were deleted to avoid model bias. The model was refined using alternate cycles of refinement in crystallography & NMR system (CNS) and model building in 'O'. The mutated residue, truncated helices, loops and the side chains were gradually added to the model, guided by the electron density map, and the model was refined further using the standard slow-cool and positional refinement protocols of CNS package using the data between 40 and 2.65 Å . The model was finally checked in a composite omit electron density map. Progressive inclusion of water molecules, the bound phosphate ion, and MES coupled with a few cycles of refinement yielded an R cryst of 21.6% (R free ¼ 27.8%). Refinement statistics are given in Table 1 .
Statistical analysis, graphs and experimental error calculations
Allelic and genotypic frequencies were calculated and compared by x 2 tests using the Statcalc software (Epi Info 2002; Centers for Disease Control and Prevention, Atlanta, GA, USA) or the Stata software version 8 (Stata Corp., College Station, TX, USA). Significance was calculated by 2 Â 2 contingency table and Fisher's exact test, to obtain P-values, OR and 95% CI. Statistical significance was considered when P , 0.05. The Breslow -Day test was used to test for homogeneity of the stratum specific ORs. This test did not indicate significant departure from homogeneity (P ¼ 0.78), thus we computed the Mantel -Haenszel test for an overall association between R263Q variant and SLE, after controlling for population. The Haploview software was used to obtain LD pairwise values. As an overall test for association of R263Q SNP independent of R620W, we performed a conditional Case -Control test implemented in the UNPHASED software (http://portal.litbio.org/Registered/Webapp/glue/).
Graphs, curve fitting, and kinetic parameter calculations were performed using the Graphpad Prism software package (Graphpad, San Diego, CA, USA). Sequence alignment was performed using ClustalW (29) . All SD of differences and ratios were calculated according to the error propagation rules described by Taylor (30) .
